EV-104 (EV Therapeutics)(EV-104 (EV Therapeutics))

概要

基本信息

药物类型

外泌体药物

别名

靶点-

作用方式-

作用机制-

治疗领域

肿瘤消化系统疾病

在研适应症-

非在研适应症

胃癌

原研机构

eV Therapeutics, Inc.

在研机构-

非在研机构

eV Therapeutics, Inc.

权益机构-

最高研发阶段终止临床前

首次获批日期-

最高研发阶段(中国)-

特殊审评-

关联

100 项与 EV-104 (EV Therapeutics) 相关的临床结果

登录后查看更多信息

100 项与 EV-104 (EV Therapeutics) 相关的转化医学

登录后查看更多信息

100 项与 EV-104 (EV Therapeutics) 相关的专利（医药）

登录后查看更多信息

1

项与 EV-104 (EV Therapeutics) 相关的文献（医药）

Emerging Infectious Diseases

Enterovirus 104 Infection in Adult, Japan, 2011

Letter

作者: Kaida, Atsushi ; Hase, Atsushi ; Sekiguchi, Jun-ichiro ; Kubo, Hideyuki ; Iritani, Nobuhiro

To the Editor: Human enterovirus (HEV) C (family Picornaviridae, genus Enterovirus) consists of 3 types of poliovirus (1, 2, and 3), 9 types of coxsackievirus A (CV-A1, 11, 13, 17, 19, 20, 21, 22, and 24), and 9 types of enterovirus (EV) (95, 96, 99, 102, 104, 105, 109, 113, and 116) (www.picornaviridae.com/enterovirus/hev-c/hev-c.htm). EV-104 was first identified in 2009 in Switzerland in 8 children who had pneumonia or acute otitis media (1). To our knowledge, there has been only 1 other report of EV-104, detected in Italy in 3 adults and 2 children who had upper respiratory tract infection (RTI) (2). We report the detection of a novel EV-104 strain in an adult with upper RTI in Japan.

100 项与 EV-104 (EV Therapeutics) 相关的药物交易

登录后查看更多信息